Centrum Medyczne Amed Sp. z o.o.
- Address
- Ul. Sw. Wincentego 93/7, 03-291 Warsaw, Poland
Cardiovascular and Metabolic Research
At Centrum Medyczne Amed Sp. z o.o. in Warsaw, clinical research in cardiovascular disease and nutritional and metabolic disease focuses on improving care for people with atherosclerotic heart and blood vessel disease and type 2 diabetes mellitus. These studies are designed to evaluate whether new approaches can better reduce cardiovascular risk, support blood sugar management, and improve the overall effectiveness of treatment.
- Testing new ways to lower the risk of major cardiovascular events in people with established artery disease
- Assessing decentralized and hybrid trial models to improve recruitment, retention, and participant experience in type 2 diabetes research
- Evaluating whether current lipid-lowering treatment strategies can be improved for patients with persistent atherosclerotic cardiovascular disease
This area combines treatment evaluation with practical research on how trials can be made more accessible and efficient for participants.
Autoimmune and Inflammatory Disease Studies
The site also supports research in immune system diseases and immune system processes, with a strong focus on psoriatic arthritis, rheumatoid arthritis, and primary Sjögren's syndrome. These trials are exploring whether newer therapies can better control inflammation, ease symptoms, and maintain long-term safety in chronic autoimmune conditions.
- Comparing treatment options for active psoriatic arthritis to see which may provide better symptom control
- Studying long-term safety and tolerability in adults living with psoriatic arthritis
- Evaluating sustained safety in patients with primary Sjögren's syndrome
- Investigating therapies for rheumatoid arthritis to improve day-to-day disease management
This research reflects a broad effort to advance both symptom relief and long-term treatment confidence in autoimmune care.
Targeted Inflammation Research in Psoriatic Arthritis
Several trials at this Warsaw site are centered on psoriatic arthritis, including active and axial forms of the disease. The goal is to test new therapies and compare them with existing options to understand how well they reduce joint pain, stiffness, and broader inflammatory symptoms.
- Evaluating whether emerging treatments can improve outcomes in active psoriatic arthritis
- Assessing relief of axial symptoms in people with psoriatic arthritis affecting the spine
- Monitoring the longer-term safety of treatments used for chronic inflammatory joint disease
This focused program highlights the site’s role in advancing care for complex inflammatory arthritis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Amed Sp. z o.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Baricitinib Versus TNF Inhibitors for Venous Thromboembolism Risk in Rheumatoid Arthritis: Phase 3b/4 Active-Controlled Study | Eli Lilly & Co. | Phase III | Not Recruiting | Jul 2019 | Apr 2025 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2019-07-25 | 2019-07-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.